Neuroprotective clinical strategies for Parkinson's disease.
作者： Ira Shoulson
关键词:
摘要: Increasing knowledge of the role brain iron in health and disease has prompted consideration therapeutic strategies aimed at attenuating effects its untoward oxidative consequences. The success this approach is critically dependent on a better understanding pathogenesis Parkinson's disease. controlled trial «Deprenyl Tocopherol Antioxidative Therapy Parkinsonism» (DATATOP) represents clinical strategy to detect neuroprotective antioxidative interventions
sci-hub.se 参考文章(12)
M.B.H. Youdim, D. Ben-Shachar, P. Riederer, Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurologica Scandinavica. ,vol. 80, pp. 47- 54 ,(1989) , 10.1111/J.1600-0404.1989.TB01782.X
B. Halliwell, Oxidants and the central nervous system: some fundamental questions: is oxidant damage relevant to Parkinson's disease, Alzheimer's disease, traumatic injury or stroke? Acta Neurologica Scandinavica. ,vol. 80, pp. 23- 33 ,(1989) , 10.1111/J.1600-0404.1989.TB01779.X
Anthony Cerami, Robert W. Grady, Charles M. Peterson, Kuldeep K. Bhargava, THE STATUS OF NEW IRON CHELATORS* Annals of the New York Academy of Sciences. ,vol. 344, pp. 425- 435 ,(1980) , 10.1111/J.1749-6632.1980.TB33682.X
D. Ben-Shachar, G. Eshel, J. P. M. Finberg, M. B. H. Youdim, The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. Journal of Neurochemistry. ,vol. 56, pp. 1441- 1444 ,(1991) , 10.1111/J.1471-4159.1991.TB11444.X
Barry Halliwell, Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action? Free Radical Biology and Medicine. ,vol. 7, pp. 645- 651 ,(1989) , 10.1016/0891-5849(89)90145-7
P. Jenner, P. Jenner, Oxidative stress as a cause of Parkinson's disease. Acta Neurologica Scandinavica. ,vol. 84, pp. 6- 15 ,(1991) , 10.1111/J.1600-0404.1991.TB05013.X
A. H. V. Schapira, J. M. Cooper, D. Dexter, J. B. Clark, P. Jenner, C. D. Marsden, Mitochondrial complex I deficiency in Parkinson's disease. Journal of Neurochemistry. ,vol. 54, pp. 823- 827 ,(1990) , 10.1111/J.1471-4159.1990.TB02325.X
L. M. Ambani, M. H. Van Woert, S. Murphy, Brain peroxidase and catalase in Parkinson disease. JAMA Neurology. ,vol. 32, pp. 114- 118 ,(1975) , 10.1001/ARCHNEUR.1975.00490440064010
Peter Riederer, Emin Sofic, Wolf-Dieter Rausch, Bruno Schmidt, Gavin P. Reynolds, Kurt Jellinger, Moussa B. H. Youdim, Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains Journal of Neurochemistry. ,vol. 52, pp. 515- 520 ,(1989) , 10.1111/J.1471-4159.1989.TB09150.X
GERALD COHEN, 16 – Oxidative Stress in the Nervous System Oxidative Stress. pp. 383- 402 ,(1985) , 10.1016/B978-0-12-642760-8.50020-X